Elahere (MIRV) keeps quality of life stable
- new analysis of the MIRASOL study
New results of the MIRASOL study were published in April 2025.
The study results showed that the drug mirvetuximab soravtansine-gynx (trade name Elahere) prolonged the time to disease progression and overall survival in patients with platinum-resistant ovarian cancer with high levels of the folic acid receptor α (FRα).
Focus on quality of life
The latest data from the study assess quality of life from the patient’s perspective (patient-reported outcomes).
This showed that Elahere can neither worsen nor clearly improve quality of life compared to conventional chemotherapy. There were slight indications of benefits, particularly for abdominal and digestive complaints: 21% of patients taking Elahere reported noticeable improvements – compared to 15% taking chemotherapy, although the difference was not entirely statistically certain. Nevertheless, in a follow-up analysis with other measurements, there were indications of actual improvements in up to 29% vs. 18%.
What does that mean in concrete terms?
No deterioration in quality of life: Women undergoing therapy with Elahere reported similar living conditions to those with standard therapy.
Symptoms remain stable: important everyday symptoms such as pain or appetite did not deteriorate.
Combination of efficacy and stability: Since Elahere has also been shown to prolong survival, it now offers a promising treatment option – without the additional burden of poor quality of life.
Why is this relevant?
Effective & well-tolerated treatment: Elahere not only postpones the disease, but also has no negative impact on patients’ everyday lives.
New option for a difficult-to-treat situation: There are only a few effective treatment options for platinum-resistant ovarian cancer – Elahere adds a solid option to this field.
Source: The Lancet Oncology (the article is in English)
